We therefore conducted HITMAN-PC, a phase I trial evaluating suba-itraconazole (SI) and hydroxychloroquine (HCQ) in men with BCR.<h4>Patients and methods</h4>The synergy of SI and HCQ was validated in hormone-sensitive and castration-resistant prostate cancer cell lines. Here, BCR is linked to prostate carcinoma.